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In-Tube and T-SPOT.TB) in testing for
latent tuberculosis infection among
HIV-infected adults
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Abstract
There is currently no ‘gold standard’ for diagnosis of latent tuberculosis infection (LTBI), and both the tuberculin skin test
and interferon-gamma release assays (IGRAs) are used for diagnosis; the latter have a higher sensitivity than tuberculin
skin tests for diagnosis of LTBI in HIV-infected individuals with lower CD4 counts. No evidence base exists for selection
of IGRA methodology to identify LTBI among human immunodeficiency virus-infected patients in the UK. We prospect-
ively evaluated two commercially available IGRA methods (QuantiFERON-TB Gold In Tube [QFG] and T-SPOT.TB) for
testing LTBI among HIV-infected patients potentially nosocomially exposed to an HIV-infected patient with ‘smear-
positive’ pulmonary tuberculosis. Among the exposed patients median CD4 count was 550 cells/mL; 105 (90%) of
117 were receiving antiretroviral therapy, of who 104 (99%) had an undetectable plasma HIV load. IGRAs were positive
in 12 patients (10.3%); QFG positive in 11 (9.4%) and T-SPOT.TB positive in six (5.1%); both IGRAs were positive in five
patients (4.3%). There was one indeterminate QFG and one borderline T-SPOT.TB result. Concordance between the
two IGRAs was moderate (¼ 0.56, 95% confidence interval¼ 0.27–0.85). IGRAs were positive in only 4 (29%) of
14 patients with previous culture-proven tuberculosis. No patient developed tuberculosis during 20 months of follow-up.
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Introduction
An estimated one-third of the world’s population is
latently infected with Mycobacterium tuberculosis.
Screening for latent tuberculosis infection (LTBI),
using either interferon-gamma release assays (IGRAs)
or tuberculin skin testing (TST), is important as it per-
mits identiﬁcation of those at greatest risk of developing
active tuberculosis, and treating LTBI reduces the risk of
progression to active disease.1 Among individuals
co-infectedwithM. tuberculosis and human immunodeﬁ-
ciency virus (HIV) and without access to antiretroviral
therapy (ART) the risk of progression to active tubercu-
losis is 10% annually.2 The risk of progression is reduced
among those receiving ART,3,4 but is still twice
that of the HIV-uninfected general population, even in
countries with a low prevalence of tuberculosis.3,4
Currently, there is no ‘gold standard’ for diagnosis
of LTBI among both immune competent and immuno-
suppressed individuals, and both TST and IGRA are
used, in single or in combination5,6; the latter appear to
have a higher sensitivity than TST for diagnosis of
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LTBI in HIV-infected individuals with CD4 counts
<200 cells/mL, and among those who have received
BCG vaccination.1,7,8 LTBI is diagnosed on the basis
of either a positive TST or IGRA result.1 The lack of a
gold standard for diagnosis of LTBI raises methodo-
logical diﬃculties in interpreting results of IGRA and
TST, both within and between studies.
The two commercially available IGRA are
QuantiFERON-TB Gold In-Tube (QFG; Cellestis,
Carnegie, Australia) and T-SPOT.TB (Oxford
Immunotech Abingdon, UK). Both assays measure
interferon-gamma released by peripheral blood mono-
nuclear cells in response to M. tuberculosis complex-
speciﬁc recombinant antigens not shared with the
BCG bacillus or most environmental mycobacterial
species. It has been suggested that among HIV-infected
individuals T-SPOT.TB has a higher sensitivity and
fewer indeterminate results than QFG.7,8 It is thought
that this is because the T-SPOT.TB assay requires a
speciﬁc number of peripheral blood mononuclear cells
and so is less likely to be aﬀected by low CD4 lympho-
cyte counts,8 however, not all studies conﬁrm this
observation.9–11
Despite accumulating evidence for the utility of
IGRA in detecting LTBI among HIV-infected patients
from low- and middle-income countries, there is a pau-
city of data from high-income countries (which have a
low prevalence of tuberculosis) and in the latter setting,
few studies have performed ‘head to head’ comparisons
of the two IGRA tests.9–12 Currently, there is no evi-
dence on which to base choice of IGRA for identifying
LTBI among HIV-infected patients in the UK (a low-
prevalence setting). In the absence of an evidence-base
on which to base a decision to use one IGRA, rather
than the other, we prospectively evaluated both QFG
and T-SPOT.TB for testing HIV-infected patients
attending an inner-London treatment centre who were
potentially nosocomially exposed to an HIV-infected
patient with smear-positive pulmonary tuberculosis.
Methods
HIV-infected patients attending an inner-London out-
patient HIV treatment centre who were potentially
nosocomially exposed to an HIV-infected patient with
smear-positive pulmonary tuberculosis were identiﬁed
from electronic patient records. The index patient
(CD4¼ 490 cells/mL, viral load¼undetectable on
ART) with known chronic obstructive pulmonary dis-
ease attended the HIV clinic with worsening respiratory
symptoms. The patient spent several hours in the clinic
waiting area prior to the diagnosis of tuberculosis.
Patients were screened between three and six months
after their exposure. For each patient, at a ‘face to face’
interview, we recorded the presence or absence of
symptoms (cough, fever, night sweats, weight loss),
gender, ethnicity, country of birth, duration of resi-
dence in UK, BCG status and prior treatment for
active (culture-conﬁrmed) tuberculosis, current CD4
count and plasma HIV load and receipt of ART.
All patients had a chest radiograph and those with a
CD4 count <200 cells/mL also had a TST, as per NICE
guidelines.6 A positive TST was deﬁned as 5mm
induration evident 48–72 h after intra-dermal injection
of 0.1mL (2 tuberculin units) of Puriﬁed Protein
Derivative (PPD). IGRA results were reported as posi-
tive, negative, indeterminate or borderline.
Statistical analysis
Data were entered into Microsoft Excel and analysed
using GraphPad Prism software v5.1 (GraphPad
Software Inc, La Jolla, CA). Concordance between
QFG and T-SPOT.TB results was assessed by kappa
() coeﬃcient.13 Strengths of agreement were con-
sidered ‘poor’,  0.20, ‘fair’, 0.20< 0.40, ‘moder-
ate’, 0.40< 0.60, ‘good’, 0.60< 0.80 and ‘very
good’, 0.80< 1.00. Correlation between median
CD4 count and concordance between IGRA results in
the present study and in recent studies from low income
countries9–12 was done using Pearson’s test; p< 0.05
was regarded as signiﬁcant.
Results
One hundred and seventeen patients were potentially
nosocomially exposed and were tested for LTBI with
both IGRAs. Of these 117 patients, 91 (78%) were men,
48 (41%) were white British, 29 (25%) black African,
21 (18%) European, seven (6%) South American and
12 (11%) were from other ethnic groups. Individuals
born outside the UK had been resident in the UK for
a median of 10 years (range 3–45). The majority,
91 (78%) of 117 had received BCG vaccination and
14 (12%) of 117 had previously been treated for cul-
ture-proven tuberculosis a median of 9.5 years previ-
ously (range¼ 3–13 years). Of the 117 patients, 116
were asymptomatic. None of the patients had active
tuberculosis at the time of screening.
Of 105 (90%) patients receiving ART, 104 (99%)
had undetectable plasma HIV loads and their median
(range) CD4 count was 530 (140–1250) cells/mL.
Among those not receiving ART the median (range)
plasma HIV load and CD4 counts were 21,000
copies/mL (590–160,000) and 520 (250–950) cells/mL,
respectively. IGRA results are shown in Table 1.
Overall there was moderate concordance between
QFG and T.SPOT.TB; ¼ 0.49 (95% conﬁdence inter-
val [CI]¼ 0.21–0.77). When indeterminate results were
excluded concordance remained moderate, ¼ 0.558
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(95% CI¼ 0.270–0.847). When those with previous
tuberculosis were excluded, concordance was lower,
¼ 0.19 (95% CI¼ 0.18–0.56).
Patients with positive IGRAs
Of all, 12 (10.3%) patients had positive IGRAs;
11 (9.4%) patients had a positive QFG result and
6 (5.1%) patients had a positive T-SPOT.TB. In ﬁve
(4.3%) both IGRAs were positive (Table 1). Their
median CD4 count was 550 (range¼ 190–920) cells/
mL; 11 patients were receiving ART. Four patients
had previously treated culture-proven tuberculosis,
making interpretation of the positive IGRA results
uncertain. Of these four patients, three had a positive
T-SPOT.TB and four had a positive QFG. Of the 12
patients, four (33%) were from the UK, four (33%)
from Central and sub-Saharan Africa, two (17%)
from West Africa and two (17%) from South/Central
America. Of these 12 patients, two opted to have
chemoprophylaxis and the others were closely moni-
tored. None of the patients have gone on to develop
active tuberculosis after 20 months of follow-up.
Patients with discordant results
Seven (6%) patients had discordant IGRA results (one
positive T.SPOT TB result, six positive QFG results).
All seven were receiving ART with a median (range)
CD4 count of 575 (190–910) cells/mL; one had previ-
ously been treated for culture-proven tuberculosis.
Patients with CD4 <200 cells/mL
Four patients (all receiving ART) had CD4 counts
<200 cells/mL; all had a negative TST. One patient
had a positive QFG result. All had previous BCG vac-
cination and none had previously been treated for cul-
ture-proven tuberculosis.
Indeterminate and borderline results
One patient had an indeterminate QFG result and one
had a borderline T-SPOT-TB result: there were no
borderline QFG results (Table 1). Both patients had
received ART for more than two years, had CD4
counts >200 cells/mL, and neither had received BCG
vaccination nor were previously treated for tuberculosis.
Previous tuberculosis
Among the 14 patients previously treated for culture-
proven active tuberculosis, 10 (71%) had received BCG;
four (29%) had a positive IGRA (in three both IGRAs
were positive, in one QFG was positive). The median
time between treatment of tuberculosis and IGRA test-
ing was 9.5 years (range 3–13) and did not diﬀer between
those who had a positive IGRA and those who did not.
All 14 individuals previously treated for tuberculosis
had undetectable HIV viral loads; 13 had received
ART for more than two years, one for 18 months.
Median CD4 counts in those with a positive IGRA
and in those without were 895 and 670 cells/mL, respect-
ively. Two of the four patients with a positive IGRA
result had abnormal chest radiographs (see below). If
those patients with a positive IGRA and a past history
of culture-conﬁrmed tuberculosis are excluded, then
seven individuals (6%) had positive QFG result and
three (2.6%) had a positive T.SPOT-TB.
Chest radiographs
Of 116 asymptomatic patients, the chest radiograph
was normal in 101, showed signs of previous ‘inactive’
tuberculosis in eight (all had previously been treated for
culture-proven tuberculosis) and evidence of other non-
infectious pathology including chronic obstructive pul-
monary disease and dilated cardiomyopathy in seven.
One patient from a country with a high-prevalence of
tuberculosis, recently arrived in the UK, and not in
receipt of ART, was symptomatic. Both QFG and
T-SPOT.TB were positive, the chest radiograph
showed hilar and mediastinal lymphadenopathy. A
whole body positron emission tomography-computed
tomography scan showed multiple 18ﬂuorodeoxy-
glucose-avid intra- and extra-thoracic lymphadenop-
athy. Histology of a lymph node biopsy showed HIV
reactive changes: mycobacterial staining and culture
were negative. With institution of ART the patient’s
symptoms and chest radiographic abnormalities
resolved. The patient declined chemoprophylaxis.
Correlation between CD4 count and concordance
between IGRA results
Examining data from recent studies9–12 and the present
study showed there was evidence of a correlation
between median CD4 count and concordance between
IGRA results; r¼ 0.92, p¼ 0.02.
Table 1. Comparison of T-SPOT.TB and QuantiFERON results
in 117 patients.
QuantiFERON
Assay Result Positive Negative Indeterminate
T-SPOT.TB Positive 5 1 0
Negative 6 103 1
Indeterminate 0 0 0
Borderline 0 1 0
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Discussion
The major ﬁndings of this study were: ﬁrst, there was a
low prevalence of positive IGRA results among this
ethnically diverse population attending an inner-
London HIV clinic who had potential nosocomial
exposure to a smear-positive patient with tuberculosis.
Twelve patients (10.3%) had a positive IGRA result;
QFG being positive in 9.4% and T-SPOT.TB positive
in 5.1%; both IGRAs were positive in 4.3%; second,
concordance between the two IGRAs was only moder-
ate; third, indeterminate results were uncommon; and
fourth, IGRAs were positive in only four of 14 (29%)
with previously treated culture-proven tuberculosis.
Most data about IGRA use among HIV-infected
patients come from studies done in high TB prevalence
regions, where patients are also likely to have more
advanced HIV disease. This poses diﬃculties in general-
ising these data to patients in the UK, where TB preva-
lence is lower and HIV care infrastructure is better
developed. This study was conducted within a cosmo-
politan and ethnically diverse population: almost 90%
patients were receiving ART, the majority had
undetectable HIV loads and the median CD4 count
was 550 cells/mL; a situation which reﬂects treatment
outcomes among HIV-infected patients without TB,
under the care of HIV specialists throughout the UK.14
Few studies have compared ‘head to head’ IGRA
testing for detection of LTBI in HIV-infected patients
in high-income countries.9–12 In none of these studies is
there a gold standard for diagnosis of LTBI. Poor,
¼ 0.06,9 ¼ 0.19,11 fair, ¼ 0.351,10 and good,
¼ 0.63512 concordance between QFG and T-
SPOT.TB have been described in studies done in
high-income settings. In the present study, concordance
was moderate, and analysis of data from these studies
shows concordant IGRA results are more likely with
higher CD4 counts. It has previously been suggested
that QFG is less sensitive than T-SPOT.TB5 for detec-
tion of LTBI, however, we demonstrated that more
subjects were QFG positive than T-SPOT.TB positive
when both tests were done in the same population. This
may indicate that QFG is superior to T.SPOT-TB for
diagnosis of LTBI, or it might be that the QFG is gen-
erating more false positive results, which is potentially a
signiﬁcant issue in low-prevalence populations such as
white UK-born HIV-infected persons who are in
receipt of ART and who have good CD4 counts.
Surprisingly, in the present study, only one-third of
individuals who had a past history of culture-proven
tuberculosis had a positive IGRA result. An explan-
ation for this observation is not immediately apparent
as the interval between TB and IGRA testing, and indi-
viduals’ CD4 counts were not diﬀerent among those
with and those without a positive IGRA result, but it
may be a reﬂection of the ﬂaws of using blood to detect
distant memory cell populations. Similar ﬁndings have
been reported in a study from Barcelona where seven of
42 HIV-infected patients being evaluated for LTBI
using both IGRA assays had a past history of TB.
Only three of the seven had a positive IGRA, and
there were no diﬀerences among those with and without
a positive IGRA result in interval between TB and
IGRA testing, nor in CD4 count.12
One of the limitations of IGRA testing among HIV-
infected patients is the rate of indeterminate results.
Previous reports from the UK describe indeterminate
T-SPOT.TB results in 2–7.4%15–17 of HIV-infected
patients; indeterminate results were no more likely
among those with CD4 counts <200 cells/mL.16,17
There are no UK data for QFG, but pooled analysis
of studies from high-income countries (that did not
include UK) found that indeterminate results with
QFG were more likely when patients had CD4 counts
<200 cells/mL, however, individual studies gave incon-
sistent results.7 Recently, a study from Alicante also
found that indeterminate QFG results were more
likely when patients had CD4 counts <200 cells/mL,
no such relationship was observed for T.SPOT TB.10
We have shown a very low rate of indeterminate IGRA
results (<1% for QFG and 0% for T.SPOT TB), most
likely due to very few patients having low CD4 counts.
Limitations of our study include the small study
population, the low rate of IGRA positivity, which pre-
cludes an analysis to identify predictors of both positive
tests and discordant results, the short duration of
follow-up (less than two years), and the fact that TST
was not done in every participant, which limits com-
parison of our ﬁndings with those from other studies.
Studies of HIV-infected persons with larger numbers
and with longer follow-up (to ﬁve years or longer), in
both higher TB prevalence settings and within Europe
and the United States, for example that proposed by
the Tuberculosis Epidemiologic Studies Consortium,18
may better help in identiﬁcation of factors predictive of
a positive IGRA, and will also help address the issue of
the relative usefulness of the TST and IGRA in predict-
ing the risk of developing active TB among HIV-
infected persons.
In the absence of a gold standard we have adopted a
pragmatic approach to detect LTBI among our current,
ethnically diverse, HIV-infected clinic population which
is based on guidelines developed by NICE6 and by
BHIVA.19 We proactively screen for LTBI using
QFG, among the following risk-groups: those present-
ing with newly diagnosed HIV infection who are from
areas with a high- or medium-prevalence of tubercu-
losis: those presenting with low CD4 counts <200
cells/mL, irrespective of their country of origin: those
with known HIV infection, who are from a high- or
medium-prevalence region and who have not received
778 International Journal of STD & AIDS 24(10)
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ART for two years or more. In those with a CD4 count
<200 cells/mL, we also perform a TST.6,19
This study provides evidence of a low rate of IGRA
positivity and a low-prevalence of LTBI among
patients in an ethnically diverse HIV-infected popula-
tion attending an inner-London outpatient treatment
centre, moderate concordance between QFG and
T.SPOT.TB in this patient group, and very low rates
of indeterminate IGRA results. It also contributes to
the evidence base for use of IGRA tests for detection of
LTBI in HIV-infected patients in the UK.
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